Churches and the Pharmaceutical Industry Urge More German Engagement for Health in Developing Countries
Berlin (GKKE / vfa). The Joint Conference Church and Development (GKKE) and the Association of Researching Pharmaceutical Companies (vfa) have advocated for increased efforts to improve health care in developing countries. In their joint statement released today, “Health in Developing Countries,” they called upon the government and parliament to expand the existing aid while making it more effective. It is hoped that this new approach will be initiated after the parliamentary elections. more
Medical Biotechnology Grows by 9 Percent in Spite of Economic Crisis
Berlin (vfa bio). “Medical biotechnology is so far proving to be resistant to the economic crisis. The turnover of biopharmaceutical products in 2008 totaled 9 percent – twice the growth of the pharmaceutical market as a whole. With an unchanged number of around 34,000 highly-qualified employees, medical biotechnology is making an important contribution to the economic and research position of Germany,” stated Dr. Frank Mathias, Chairman of vfa bio and a member of the Board of Directors for MediGene AG, Martinsried, at the presentation of the industry report “Medical Biotechnology 2009”. The report was issued by The Boston Consulting Group (BCG) for vfa bio, the interest group for biotechnology at the vfa. It analyzed the activities of German biotech start-up companies as well as larger biotech firms and pharmaceutical companies active in medical biotechnology. more
Researching Pharmaceutical Companies to Come Out with 10 New Malaria Drugs
Berlin (vfa). Each year more than 800,000 people die worldwide from malaria infections. Children under 5 years of age in southern Africa are most at risk. The newest medications, provided by researching pharmaceutical companies under special conditions, are mostly quite effective, but the first cases of resistant agents are appearing. “Researching pharmaceutical companies are therefore developing ten new malaria medications, which are either in clinical studies or have already been submitted for approval. There are also a further 14 projects currently underway in laboratories,” declared Cornelia Yzer, the CEO of the Association for Researching Pharmaceutical Companies (vfa), with a view to World Malaria Day on April 25. more
Citizens Expect Further Reform
Berlin (vfa). Researching pharmaceutical companies commissioned Emnid to conduct a representative survey of the general opinion of health care policy in Germany. Here are the most significant findings, presented today at the polling institute by Klaus-Peter Schöppner. more
Fighting Tuberculosis through Research, Therapy und Awareness
Berlin (vfa). “Tuberculosis is malicious – hardly any other infectious disease is as difficult to treat as this disease. And hardly any other claims so many victims worldwide: every minute three people die as a result. Annually that translates into almost 1.7 million victims, the majority in poor countries. Tuberculosis can be successfully fought, however – and we do just that through research, therapy and awareness,” explains Dr. Wolfgang Plischke, the vfa's chairman of the board of directors, with a view to World Tuberculosis Day on March 24. more
VFA is the first pharmaceutical association to enter the voluntary European lobby register
Berlin (VFA). On September 17, 2008, the German Association of Research-based Pharmaceutical Companies (VFA) was the first pharmaceutical association in Europe to enter the voluntary Register of Interest Representatives with the European Commission. more
Pharmaceutical industry demands an initiative on behalf of Germany as an industrial location
Berlin (VFA) – What did two and a half years of the Grand Coalition do for Germany as a location for the pharmaceutical industry? To answer this question, the German Association of Research-based Pharmaceutical Companies (VFA) commissioned Prof. Dr. Thomas Straubhaar of the Hamburg Institute of International Economics (HWWI) to carry out a study reviewing the policy of the Grand Coalition in terms of Germany as a location for the pharmaceutical industry. more
The job engine of biotechnology runs hot
Berlin (VFA). "A total of 4,000 new jobs, an increase of 14 percent in just one year, is the proud result of medical biotechnology in Germany. The 'job engine of biotechnology' is running hot," Dr. Frank Mathias, chairman of VFA Bio and member of the executive board of MediGene AG in Martinsried, said during the presentation of the industry report entitled "Medical Biotechnology in Germany 2008" in Berlin. The report was developed by the Boston Consulting Group (BCG) on behalf of VFA Bio, the interest group for biotechnology within the German Association of Research-based Pharmaceutical Companies (VFA). The annually published report is the only one to cover all activities in the field of medical biotechnology in Germany – in start-up companies as well as large corporations. more
Printer-friendly copy 
News
Expense forecast:Increase for medical reasons
G8 summit:
Setting the correct course for combating AIDS in Africa
Cost-Benefit Assessment in Germany:
Orientation by international standards
Aus F&E
PharmakogenetikIn Deutschland zugelassene Arzneimittel für die individualisierte Medizin
Arzneimittelentwicklung:
Patienten und Ärzte hoffen auf bessere Behandlungsmöglichkeiten - und die Chancen dafür sind gut: Bis Ende 2013 können gegen rund 130 Krankheiten neue Medikamente herauskommen
Gerinnungshemmer:
Thrombosen, Embolien und Schlaganfälle: Besser vorbeugen